The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy
Open accessAbstract
Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and autoimmune disease. However, the cellular and molecular pathways for B cell depletion remain undefined because human mechanistic studies are limited. Proposed mechanisms include antibody-, effector cell–, and complement-dependent cytotoxicity, the disruption of CD20 signaling pathways, and the induction of apoptosis. To identify the mechanisms for B cell depletion in vivo, a new mouse model for anti-CD20 immunotherapy was developed using a panel of twelve mouse anti–mouse CD20 monoclonal antibodies representing all four immunoglobulin G isotypes. Anti-CD20 antibodies rapidly depleted the vast majority of circulating and tissue B cells in an isotype-restricted manner that was completely dependent on effector cell Fc receptor expression. B cell depletion used both FcγRI- and FcγRIII-dependent pathways, whereas B cells were not eliminated in FcR common γ chain–deficient mice. Monocytes were the dominant effector cells for B cell depletion, with no demonstrable role for T or natural killer cells. Although most anti-CD20 antibodies activated complement in vitro, B cell depletion was completely effective in mice with genetic deficiencies in C3, C4, or C1q complement components. That the innate monocyte network depletes B cells through FcγR-dependent pathways during anti-CD20 immunotherapy has important clinical implications for anti-CD20 and other antibody-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Rooijen, N. V., & Sanders, A. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90012-4 · Cited by 1,779
Kägi, D., Ledermann, B., Bürki, K., Seiler, P., Odermatt, B., Olsen, K. J., Podack, E. R., Zinkernagel, R. M., & Hengartner, H. (1994) · Nature · doi:10.1038/369031a0 · Cited by 1,757
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor
Samuelsson, A., Towers, T. L., & Ravetch, J. V. (2001) · Science · doi:10.1126/science.291.5503.484 · Cited by 1,053
Self-citationFcR γ chain deletion results in pleiotrophic effector cell defects
Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951
Self-citationCoiffier, B., Haïoun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D. D. F., Johnson, P., Lister, A., Feuring‐Buske, M., Radford, J. A., et al. (1998) · PubMed · doi:10.1182/blood.v92.6.1927 · Cited by 893
Repeat-induced gene silencing in mammals
Garrick, D., Fiering, S., Martin, D. I. K., & Whitelaw, E. (1998) · Nature Genetics · doi:10.1038/ng0198-56 · Cited by 887
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Maloney, D. G., Grillo-López, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 636
Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604
CD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
Self-citationApoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Cecchini, M. G., Dominguez, M. G., Mocci, S., Wetterwald, A., Felix, R., Fleisch, H., Chisholm, O., Hofstetter, W., Pollard, J. W., & Stanley, E. R. (1994) · Development · doi:10.1242/dev.120.6.1357 · Cited by 565
Essential Role of LAT in T Cell Development
Zhang, W., Sommers, C. L., Burshtyn, D. N., Stebbins, C. C., DeJarnette, J. B., Trible, R. P., Grinberg, A., Tsay, H. C., Jacobs, H. M., Kessler, C. M., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80032-1 · Cited by 547
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J. C. W., & Cambridge, G. (2001) · Rheumatology · doi:10.1093/rheumatology/40.2.205 · Cited by 523
Wessels, M. R., Butko, P., Ma, M., Warren, H. B., Lage, A. L., & Carroll, M. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11490 · Cited by 503
Impaired IgG-Dependent Anaphylaxis and Arthus Reaction in FcγRIII (CD16) Deficient Mice
Hazenbos, W. L. W., Gessner, J. E., Hofhuis, F. M. A., Kuipers, H., Meyer, D., Heijnen, I. A. F. M., Schmidt, R. E., Sandor, M., Capel, P. J. A., Daëron, M., et al. (1996) · Immunity · doi:10.1016/s1074-7613(00)80494-x · Cited by 443
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., & Bonavida, B. (1997) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1997.12.177 · Cited by 394
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050016 · Cited by 385
Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy
Silverman, G. J., & Weisman, S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10947 · Cited by 367
DIVERGENT ROLES FOR F c RECEPTORS AND COMPLEMENT IN VIVO
Ravetch, J. V., & Clynes, R. A. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.421 · Cited by 366
Self-citationAntibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360
Complement activation plays a key role in the side‐effects of rituximab treatment
Van Der Kolk, L. E., Grillo‐López, A. J., Baars, J. W., Hack, C. E., & Van Oers, M. H. J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03166.x · Cited by 327
Ioan-Facsinay, A., de Kimpe, S. J., Hellwig, S. M. M., van Lent, P. L., Hofhuis, F. M. A., van Ojik, H. H., Sedlik, C., da Silveira, S. A., Gerber, J., de Jong, Y. F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00294-7 · Cited by 304
Bruhns, P., Samuelsson, A., Pollard, J. W., & Ravetch, J. V. (2003) · Immunity · doi:10.1016/s1074-7613(03)00080-3 · Cited by 304
Self-citationStory, J. A., & Kritchevsky, D. (1981) · PubMed · Cited by 274
Sato, S., Ono, N., Steeber, D. A., Pisetsky, D. S., & Tedder, T. F. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.10.4371 · Cited by 267
Self-citationAnderson, D. R., Grillo-López, A., Varns, C., Chambers, K. S., & Hanna, N. (1997) · Biochemical Society Transactions · doi:10.1042/bst0250705 · Cited by 248
Mouse CD20 expression and function
Uchida, J. (2004) · International Immunology · doi:10.1093/intimm/dxh009 · Cited by 244
Self-citationActivation of mouse complement by monoclonal mouse antibodies
Neuberger, M. S., & Rajewsky, K. (1981) · European Journal of Immunology · doi:10.1002/eji.1830111212 · Cited by 231
Weng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218
Farag, S. S., Flinn, I. W., Modali, R., Lehman, T. A., Young, D., & Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2003-07-2548 · Cited by 210
Treon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., & Anderson, K. C. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200105000-00011 · Cited by 205
Bellosillo, B., Villamor, N., López-Guillermo, A., Marcé, S., Esteve, J., Campo, E., Colomer, D., & Montserrat, E. (2001) · Blood · doi:10.1182/blood.v98.9.2771 · Cited by 205
Immunoglobulin G–mediated Inflammatory Responses Develop Normally in Complement-deficient Mice
Sylvestre, D., Clynes, R., Ma, M., Warren, H., Carroll, M. C., & Ravetch, J. V. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.6.2385 · Cited by 202
Self-citationDi Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., & Introna, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03014.x · Cited by 198
Fossati-Jimack, L., Ioan-Facsinay, A., Reininger, L., Chicheportiche, Y., Watanabe, N., Saito, T., Hofhuis, F. M. A., Gessner, J. E., Schiller, C., Schmidt, R. E., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.8.1293 · Cited by 180
Inflammation in autoimmunity: receptors for IgG revisited
Dijstelbloem, H. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02014-2 · Cited by 176
Mathas, S., Rickers, A., Bommert, K., Dörken, B., & Mapara, M. Y. (2000) · PubMed · Cited by 155
da Silveira, S. A., Kikuchi, S., Fossati‐Jimack, L., Moll, T., Saito, T., Verbeek, J. S., Botto, M., Walport, M. J., Carroll, M. C., & Izui, S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012024 · Cited by 149
Ansell, S. M., Witzig, T. E., Kurtin, P. J., et al. (2002) · Blood · doi:10.1182/blood.v99.1.67 · Cited by 148
Onrust, S. V., Lamb, H. M., & Balfour, J. A. B. (1999) · Drugs · doi:10.2165/00003495-199958010-00009 · Cited by 142
Kennedy, A. D., Solga, M. D., Schuman, T. A., Chi, A. W., Lindorfer, M. A., Sutherland, W. M., Foley, P. L., & Taylor, R. P. (2003) · Blood · doi:10.1182/blood-2002-03-0876 · Cited by 141
Liu, A. Y. C., Robinson, R. R., Murray, E., Ledbetter, J. A., Hellström, I., & Hellström, K. E. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.10.3521 · Cited by 140
Zhou, L., Smith, H. M., Waldschmidt, T. J., Schwarting, R., Daley, J. F., & Tedder, T. F. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3884-3894.1994 · Cited by 134
Self-citationAl, G., Barnes, N. C., Dijstelbloem, H. M., & Hogarth, P. M. (1998) · PubMed · Cited by 130
Meyer, D., Schiller, C., Westermann, J., Izui, S., Hazenbos, W. L. W., Verbeek, J. S., Schmidt, R. E., & Gessner, J. E. (1998) · Blood · doi:10.1182/blood.v92.11.3997 · Cited by 124
Influence of antibody isotype on passive serotherapy of lymphoma.
Denkers, E., Badger, C. C., Ledbetter, J. A., et al. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.3.2183 · Cited by 107
Immunotherapy of Non-Hodgkin's Lymphomas
Press, O. W., Leonard, J. P., Coiffier, B., Levy, R., & Timmerman, J. M. (2001) · Hematology · doi:10.1182/asheducation-2001.1.221 · Cited by 103
Gavin, A. L., Barnes, N. C., Dijstelbloem, H. M., & Hogarth, P. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.1.20 · Cited by 103
Elsässer, D., Valerius, T., Repp, R., Weiner, G. J., Deo, Y. M., Kalden, J., van de Winkel, J. G. J., Stevenson, G., Glennie, M. J., & Gramatzki, M. (1996) · Blood · doi:10.1182/blood.v87.9.3803.bloodjournal8793803 · Cited by 86
High Pathogenic Potential of Low-Affinity Autoantibodies in Experimental Autoimmune Hemolytic Anemia
Fossati‐Jimack, L., Reininger, L., Chicheportiche, Y., Clynes, R., Ravetch, J. V., Honjo, T., & Izui, S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1689 · Cited by 86
Self-citationClinical status and optimal use of rituximab for B-cell lymphomas.
McLaughlin, P. J., White, C. A., Grillo-López, A. J., & Maloney, D. G. (1998) · PubMed · Cited by 84
Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils
van der Kolk, L., de Haas, M., Grillo-López, A. J., Baars, J. W., & van Oers, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402424 · Cited by 68
Stockmeyer, B., Elsässer, D., Dechant, M., Repp, R., Gramatzki, M., Glennie, M. J., van de Winkel, J. G. J., & Valerius, T. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00346-x · Cited by 65
A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody
Gazzano, H., Ralph, P., Ryskamp, T., Chen, A. B., & Mukku, V. R. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00002-1 · Cited by 55
Isaacs, J. D., Greenwood, J., & Waldmann, H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.8.3862 · Cited by 49
Isaacs, J. D., Greenwood, J., & Waldmann, H. (1998) · PubMed · Cited by 47
Stockmeyer, B., Schiller, M. R., Repp, R., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03722.x · Cited by 38
What is meant by self-management and how can its efficacy be established?
Newman, S. P. (2001) · British journal of rheumatology · doi:10.1093/rheumatology/40.1.1 · Cited by 35
Cited by
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Self-citationMacrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Self-citationB lymphocytes: how they develop and function
LeBien, T. W., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-02-078071 · Cited by 1,400
Self-citationYanaba, K., Bouaziz, J.-D., Haas, K. M., Poe, J. C., Fujimoto, M., & Tedder, T. F. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.017 · Cited by 1,238
Self-citation
Metadata
- Authors
- Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2004-06-21
- Volume
- 199
- Issue
- 12
- Pages
- 1659-1669
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2108556253
- Cited by
- 642
- References
- 73
- FWCI
- 28.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.